Compare HIMX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | HRMY |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2006 | 2020 |
| Metric | HIMX | HRMY |
|---|---|---|
| Price | $13.50 | $42.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.2M | 679.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $14.94 | $19.75 |
| Revenue Next Year | $7.79 | $12.88 |
| P/E Ratio | ★ $14.99 | $22.42 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $6.85 | $25.52 |
| 52 Week High | $25.09 | $41.49 |
| Indicator | HIMX | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 70.60 |
| Support Level | $13.02 | $34.87 |
| Resistance Level | $15.91 | N/A |
| Average True Range (ATR) | 0.49 | 1.19 |
| MACD | -0.05 | 0.22 |
| Stochastic Oscillator | 14.20 | 99.03 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.